{"id":2411,"date":"2025-12-04T17:18:17","date_gmt":"2025-12-05T01:18:17","guid":{"rendered":"https:\/\/puny-toaster.flywheelstaging.com\/?p=2411"},"modified":"2026-09-19T20:21:06","modified_gmt":"2026-09-20T03:21:06","slug":"first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial","status":"publish","type":"post","link":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/","title":{"rendered":"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial"},"content":{"rendered":"<ul>\n<li><em>The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Consultants, in Sacramento, California.<\/em><\/li>\n<li><em>SAPPHIRE Trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of VisiPlate\u00ae aqueous shunt in glaucoma patients.<\/em><\/li>\n<li><em>VisiPlate\u00ae shunt is uniquely designed: novel metamaterial, thinner than a human hair, aiming for longevity, comfort, and aesthetics.<\/em><\/li>\n<\/ul>\n<p>Redwood City, CA \u2013 December 2, 2025 &#8211; \/<a href=\"https:\/\/www.ophthalmologytimes.com\/view\/avisi-technologies-treats-first-patient-in-sapphire-trial-for-glaucoma\">Ophthalmology Times<\/a>\/ Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces the first patient in the international SAPPHIRE Trial has been treated with Avisi\u2019s glaucoma treatment device VisiPlate\u00ae. SAPPHIRE (NCT07220876) is a prospective, multicenter, open-label trial, evaluating the safety and effectiveness outcomes of VisiPlate in patients with Open-Angle Glaucoma (OAG).<\/p>\n<p>The first VisiPlate\u00ae surgery was performed by study investigator Dr. Kiersten Snyder. Dr. Snyder, along with Principal Investigator Dr. Jacob W. Brubaker, were enthusiastic about the device and surgery. Remarking on the surgeon experience, Dr. Snyder, shared \u201cThe VisiPlate is a remarkable technology showcasing a thin and flexible design for controlled aqueous outflow. It was also easy to install.\u201d<\/p>\n<p>VisiPlate\u00ae is a novel glaucoma treatment device engineered to sustainably reduce intraocular pressure (IOP) by improving outflow of aqueous. The VisiPlate\u00ae device is designed with multiple and redundant microchannels to provide sustained aqueous flow while minimizing the risk of blockage and re-intervention. The device is made of ultrathin, biocompatible materials that seek to avoid longstanding reasons for failure of existing glaucoma treatment options. VisiPlate\u00ae has been previously studied in the VITA Trial with long-term follow up data presented at the 2025 American Academy of Ophthalmology annual meeting.<\/p>\n<p>\u201cVisiPlate is an advanced technology designed to maximize patients\u2019 quality of life. Dr. Snyder\u2019s successful VisiPlate surgery progresses a needed solution for managing glaucoma and preserving vision.\u201d said the Founder and CEO, Rui Jing Jiang. \u201cWe are grateful for the expertise of our physician collaborators and look forward to treating more glaucoma patients through the SAPPHIRE trial.\u201d<\/p>\n<p>The SAPPHIRE trial is currently active in several sites across the US, including:<\/p>\n<ul>\n<li>Arizona Advanced Eye Research, Glendale, Arizona, United States, 85306<\/li>\n<li>Glaucoma Associates of Texas, Dallas, Texas, United States, 75231<\/li>\n<li>ICON Eye Care, Grand Junction, Colorado, United States, 81501<\/li>\n<li>Sacramento Eye Consultants, Sacramento, California, United States, 95815<\/li>\n<li>The Eye Centers of Racine &amp; Kenosha, Kenosha, Wisconsin, United States, 53142<\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">More site activations are\u00a0scheduled for\u00a02026.\u00a0Approximately 65 patients\u00a0will be\u00a0treated\u00a0in the SAPPHIRE Trial across 13\u00a0locations, and the resulting data is\u00a0anticipated\u00a0to support future\u00a0FDA applications.\u00a0This trial will\u00a0evaluate the\u00a0safety and effectiveness of\u00a0the\u00a0VisiPlate<\/span><span data-contrast=\"auto\">\u00ae<\/span><span data-contrast=\"auto\">\u00a0aqueous shunt in\u00a0patients with OAG.\u00a0The primary endpoint\u00a0of the trial\u00a0is\u00a0the\u00a0proportion of subjects achieving\u00a0clinically significant\u00a0reduction\u00a0in\u00a0diurnal IOP\u00a0at 12 months compared to\u00a0baseline, on the same or fewer number of glaucoma medications. Important\u00a0safety evaluations and patient\u00a0feedback, including\u00a0vision quality, will be\u00a0obtained through 12 months.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About\u00a0VisiPlate\u00ae<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Avisi Technologies&#8217;\u00a0<\/span><a href=\"https:\/\/avisitech.com\/ja\/visiplate\/\"><b><span data-contrast=\"none\">VisiPlate<\/span><\/b><b><span data-contrast=\"none\">\u00ae<\/span><\/b><\/a><b><span data-contrast=\"auto\">\u00a0<\/span><\/b><span data-contrast=\"auto\">aqueous\u00a0shunt is a unique\u00a0device\u00a0made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than\u00a0a human\u00a0hair. The device is both doctor and patient-centric, designed for ease of implantation, longevity, comfort, and aesthetics. Its multiple, redundant microchannels are engineered to provide\u00a0sustained\u00a0aqueous flow while minimizing the risk of blockage\u00a0and re-intervention,\u00a0both\u00a0common challenges\u00a0with currently available glaucoma surgical solutions.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About Glaucoma and\u00a0Current\u00a0Treatment:<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/avisitech.com\/ja\/what-is-glaucoma-ja\/\"><b><span data-contrast=\"none\">Glaucoma<\/span><\/b><\/a><span data-contrast=\"auto\">\u00a0is\u00a0the leading cause of irreversible blindness worldwide,\u00a0affecting over 133\u00a0million\u00a0people\u00a0according to Market Scope\u2019s 2025\u00a0Glaucoma Surgical Device Market Report,\u00a0and currently has no cure. In glaucoma patients, excess fluid\u00a0builds up\u00a0within the eye, increasing pressure on the optic\u00a0nerve\u00a0and leading to permanent vision loss. Glaucoma is a group of diseases, the most common of which are open-angle glaucoma (OAG) and angle-closure glaucoma.<\/span><span data-ccp-props=\"{&quot;335557856&quot;:16777215,&quot;335559739&quot;:525}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">OAG\u00a0often has no early warning signs or symptoms. It occurs when the\u00a0eye&#8217;s\u00a0drainage system (trabecular meshwork) becomes clogged, preventing normal fluid outflow and leading to elevated eye pressure. Without diagnosis and treatment, OAG can cause gradual vision loss over time.\u00a0Current treatments for glaucoma include medications, lasers, surgeries, and medical device solutions. However, these interventions rely on patient compliance, re-treatment,\u00a0or may fail due to occlusion and scarring over time.\u00a0There\u00a0remains\u00a0a pressing need for safe and effective long-term treatments for glaucoma that improve patient outcomes and quality of life.\u00a0<\/span><span data-ccp-props=\"{&quot;335557856&quot;:16777215,&quot;335559739&quot;:525}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About\u00a0Avisi Technologies<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/avisitech.com\/ja\/\"><b><span data-contrast=\"none\">Avisi Technologies<\/span><\/b><\/a><span data-contrast=\"auto\">\u00a0is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company&#8217;s portfolio includes\u00a0state-of-the-art\u00a0treatments for glaucoma and other ocular conditions. These include its flagship\u00a0VisiPlate\u00ae aqueous shunt,\u00a0V-001\u00a0sustained\u00a0intraocular\u00a0drug-delivery platform, and\u00a0the\u00a0VisiPlate-S\u00a0drainage device for treating\u00a0glaucoma\u00a0at the time of cataract surgery. Avisi\u00a0has been\u00a0recognized and supported\u00a0by\u00a0numerous\u00a0organizations, including the National Science Foundation\u00a0(NSF), the Glaucoma Research Foundation, SXSW, Johnson &amp; Johnson JLABs, Medtech Innovator Accelerator, UCSF Rosenman Institute, and the University of Pennsylvania, among others. Avisi\u00a0is\u00a0funded by venture capital investors, angel investors, and\u00a0scientific\u00a0research grants. For more information, visit\u00a0<\/span><a href=\"https:\/\/avisitech.com\/ja\/\"><b><span data-contrast=\"none\">avisitech.com<\/span><\/b><\/a><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;335557856&quot;:16777215}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0is an investigational device. The\u00a0VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0device is for investigational use only, and\u00a0not\u00a0yet available for sale.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n<p><b><i><span data-contrast=\"none\">Media\u00a0Contact:<\/span><\/i><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"none\">Seth Harrington<\/span><\/i><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><a href=\"mailto:info@avisitech.com\"><b><i><span data-contrast=\"none\">info@avisitech.com<\/span><\/i><\/b><\/a><br \/>\n<span data-contrast=\"none\">More information on the\u00a0<\/span><a href=\"https:\/\/avisitech.com\/clinical-trials-at-avisi-technologies\/\"><span data-contrast=\"none\">SAPPHIRE<\/span><\/a><span data-contrast=\"none\">\u00a0clinical trial<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"auto\">SOURCE: Avisi Technologies, Inc.<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Con [&hellip;]<\/p>\n","protected":false},"author":486,"featured_media":1686,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[150],"tags":[],"class_list":["post-2411","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial - Avisi Technologies Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial - Avisi Technologies Inc.\" \/>\n<meta property=\"og:description\" content=\"The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Con [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Avisi Technologies Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-05T01:18:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-20T03:21:06+00:00\" \/>\n<meta name=\"author\" content=\"ivankornienko\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ivankornienko\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/\"},\"author\":{\"name\":\"ivankornienko\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\"},\"headline\":\"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial\",\"datePublished\":\"2025-12-05T01:18:17+00:00\",\"dateModified\":\"2026-09-20T03:21:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/\"},\"wordCount\":881,\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Ophth-Times-Image.avif\",\"articleSection\":[\"News\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/\",\"name\":\"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial - Avisi Technologies Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Ophth-Times-Image.avif\",\"datePublished\":\"2025-12-05T01:18:17+00:00\",\"dateModified\":\"2026-09-20T03:21:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Ophth-Times-Image.avif\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Ophth-Times-Image.avif\",\"width\":1200,\"height\":800,\"caption\":\"(Image Credit: AdobeStock\\\/hin255)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\",\"name\":\"Avisi Technologies Inc.\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\",\"name\":\"Avisi Technologies Inc.\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"width\":124,\"height\":43,\"caption\":\"Avisi Technologies Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\",\"name\":\"ivankornienko\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"caption\":\"ivankornienko\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial - Avisi Technologies Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/","og_locale":"ja_JP","og_type":"article","og_title":"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial - Avisi Technologies Inc.","og_description":"The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Con [&hellip;]","og_url":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/","og_site_name":"Avisi Technologies Inc.","article_published_time":"2025-12-05T01:18:17+00:00","article_modified_time":"2026-09-20T03:21:06+00:00","author":"ivankornienko","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ivankornienko","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/#article","isPartOf":{"@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/"},"author":{"name":"ivankornienko","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5"},"headline":"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial","datePublished":"2025-12-05T01:18:17+00:00","dateModified":"2026-09-20T03:21:06+00:00","mainEntityOfPage":{"@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/"},"wordCount":881,"publisher":{"@id":"https:\/\/avisitech.com\/ja\/#organization"},"image":{"@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/12\/Ophth-Times-Image.avif","articleSection":["News"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/","url":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/","name":"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial - Avisi Technologies Inc.","isPartOf":{"@id":"https:\/\/avisitech.com\/ja\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/#primaryimage"},"image":{"@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/12\/Ophth-Times-Image.avif","datePublished":"2025-12-05T01:18:17+00:00","dateModified":"2026-09-20T03:21:06+00:00","breadcrumb":{"@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/#primaryimage","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/12\/Ophth-Times-Image.avif","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/12\/Ophth-Times-Image.avif","width":1200,"height":800,"caption":"(Image Credit: AdobeStock\/hin255)"},{"@type":"BreadcrumbList","@id":"https:\/\/avisitech.com\/ja\/first-patient-implanted-with-visiplate-glaucoma-treatment-device-in-the-sapphire-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/avisitech.com\/ja\/"},{"@type":"ListItem","position":2,"name":"First Patient Implanted with VisiPlate\u00ae Glaucoma Treatment Device in the SAPPHIRE Trial"}]},{"@type":"WebSite","@id":"https:\/\/avisitech.com\/ja\/#website","url":"https:\/\/avisitech.com\/ja\/","name":"Avisi Technologies Inc.","description":"","publisher":{"@id":"https:\/\/avisitech.com\/ja\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avisitech.com\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/avisitech.com\/ja\/#organization","name":"Avisi Technologies Inc.","url":"https:\/\/avisitech.com\/ja\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/logo\/image\/","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","width":124,"height":43,"caption":"Avisi Technologies Inc."},"image":{"@id":"https:\/\/avisitech.com\/ja\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5","name":"ivankornienko","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","caption":"ivankornienko"}}]}},"_links":{"self":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/users\/486"}],"replies":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/comments?post=2411"}],"version-history":[{"count":1,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2411\/revisions"}],"predecessor-version":[{"id":2414,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2411\/revisions\/2414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/media\/1686"}],"wp:attachment":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/media?parent=2411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/categories?post=2411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/tags?post=2411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}